Martin Sipkoff
MANAGED CARE September 2007. ©MediMedia USA

Thanks to recent Supreme Court rulings, manufacturers of generic drugs are in a good position to continue expansion of their market share

Laws are evolving in favor of the generics industry as the demand for generics grows. Several recent Supreme Court decisions in particular are having a significant effect on the industry — decisions that some pharmacy directors say may increase the availability and demand for generic drugs.

"We are seeing an evolving situation that seems to favor the increased use of generics," says Glen Stettin, MD, vice president for clinical products at Medco Health Solutions. "More products will be coming to the market as blockbuster patents end this year and especially next, and some companies are finding the path to market less encumbered. Certainly the demand for generics is increasing among our customers, the employers, and health plans."

The generics market certainly is strong, having grown swiftly between 2001 and 2004, primarily because of the patent expirations of blockbuster drugs. According to IMS Health, the total generics market in this country went from 49 percent of all prescriptions sold in 2000 to 64 percent at the end of the first quarter of this year — 20 percent of all dollars spent on drugs. It went from 60 percent to 63 percent in the last two years alone.

All of this makes the generics industry an increasingly powerful economic force. Its power in the health care industry could increase as the recent Supreme Court decisions ripple through the market.

One decision in particular — which had nothing to do with drugs — could have a major effect. At issue is what has come to be called the "obviousness test." In KSR v. Teleflex, the Court ruled last April that "granting patent protection to advances that would occur in the ordinary course without real innovation retards progress" and may deprive "inventions of their value or utility."

The ruling strengthens generic manufacturer claims that patents for extended-release versions of previously patented drugs are vulnerable to challenge, as well as drugs that are re-patented when the delivery system is changed, like a tablet that is changed into a gelatin capsule.

"This will have implications for the pharmaceutical industry because generics manufacturers will take advantage of it," says Bryan A. Liang, professor of health law studies at California Western School of Law in San Diego.

Another Supreme Court action seems to favor branded generics, i.e., generic drugs either manufactured by branded companies or manufactured as the result of deals between generics and brand-name companies. Branded generics are also called authorized generics.

In June the Supreme Court refused to consider the appeal of a lawsuit brought by consumer groups against AstraZeneca and the generics manufacturer Barr Laboratories. The court let stand a ruling that an agreement between the two companies regarding the sale of a generic version of AstraZeneca's Nolvadex breast-cancer drug did not violate antitrust laws.

Discount discussion

The consumer groups, joined by some labor union health plans, claimed that a 1993 agreement between Barr and Zeneca, a predecessor to AstraZeneca, blocked the sale of lower-cost generic versions. Zeneca had paid Barr $21 million to settle its challenge to the patent for Nolvadex, the chemical name for tamoxifen citrate, and gave Barr the right to sell tamoxifen made by AstraZeneca. Barr was selling the drug at an agreed 5-percent discount to AstraZeneca's price. The plaintiffs said the generic version would have sold for a far greater discount had it not been for the agreement.

The decision will play a major role in the generics market in coming years. It allows brand manufacturers to successfully compete with generic drug manufacturers whose products are considerably less expensive through deals similar to the one between AstraZeneca and Barr.

Illegal strategy

That said, it has not been all good news for Big Pharma and the generics companies they cut deals with to manufacture authorized generics. A Supreme Court decision in February found that one strategy used by brand pharmaceutical manufacturers to delay competition from lower-cost generics was illegal.

In MedImmune v. Genentech, the court nullified a federal district court ruling that made it harder for manufacturers of generics to file a new abbreviated drug application with the FDA.

Manufacturers of generics sometimes ask courts to approve their right to file a NADA before they actually file with the FDA. The Supreme Court's action means that when seeking the approval, known as "declaratory relief, they no longer need to have "reasonable apprehension" that a brand manufacturer will attempt to block the NADA.

Generic Pharmaceutical Association President and Chief Executive Officer Kathleen Jaeger said in a public statement that "the Supreme Court has ruled in favor of American consumers by making it harder for brand companies to delay generics from coming to market."

According to Jaeger, studies show that authorized generics "significantly reduce incentives for independent generic firms to challenge invalid brand name patents and to develop non-infringing processes."

"The long-term effect of allowing authorized generics on the market during the 180-day generic exclusivity period will be less competition and reduced access to cheaper drugs," according to GPhA.

These decisions mean the generics industry will continue to gain market share.

Contributing Editor Martin Sipkoff is a long-time health care journalist.

Several major patent expirations to occur this year

In 2006, the major therapeutic class to go generic was statins: Merck's Zocor (simvastatin) and Bristol-Myers Squibb's Pravachol (pravastatin). In 2005, it was antidepressants. This year no major therapeutic class went generic. Next year, however, proton pump inhibitors will have a second big entrant in the generics market, and this will probably boost the market.

According to the Generic Pharmaceutical Association, the following drugs are either off or coming off patent this year or next.

Brand Generic Manufacturer Patent Expiration
Lotrel amlodipine and benazepril Novartis Jan. 31, 2007
Norvasc amlodipine Pfizer Jan. 31, 2007
Actiq fentanyl transmucosal Cephalon Feb. 5, 2007
Aceon perindopril Solvay Feb. 21, 2007
Alocril nedocromil Allergan April 2, 2007
Imitrex sumatriptan GlaxoSmithKline June 28, 2007
Coreg carvedilol GlaxoSmithKline Sept. 5, 2007
Meridia sibutramine Abbott Dec. 11, 2007
Mavik trandolapril Abbott Laboratories Dec. 12, 2007
Tequin gatifloxacin GlaxoSmithKline Dec. 25, 2007
Zyrtec cetirizine Pfizer Dec. 25, 2007
Fosamax alendronate Merck Feb. 6, 2008
Camptosar irinotecan Pfizer Feb. 20, 2008
Effexor/XR venlafaxine Wyeth June 13, 2008
Zymar gatifloxacin Allergan June 25, 2008
Dovonex calcipotriene Bristol-Myers Squibb June 29, 2008
Kytril granisetron Roche June 29, 2008
Risperdal risperidone Janssen June 29, 2008
Depakote divalproex sodium Abbott July 29, 2008
Advair fluticasone and salmeterol GlaxoSmithKline August 12, 2008
Serevent salmeterol GlaxoSmithKline August 12, 2008
Casodex bicalutamide Bristol-Myers Squibb Oct. 1, 2008
Trusopt dorzolamide Merck Oct. 28, 2008
Zerit stavudine Bristol-Myers Squibb Dec. 24, 2008

Managed Care’s Top Ten Articles of 2016

There’s a lot more going on in health care than mergers (Aetna-Humana, Anthem-Cigna) creating huge players. Hundreds of insurers operate in 50 different states. Self-insured employers, ACA public exchanges, Medicare Advantage, and Medicaid managed care plans crowd an increasingly complex market.

Major health care players are determined to make health information exchanges (HIEs) work. The push toward value-based payment alone almost guarantees that HIEs will be tweaked, poked, prodded, and overhauled until they deliver on their promise. The goal: straight talk from and among tech systems.

They bring a different mindset. They’re willing to work in teams and focus on the sort of evidence-based medicine that can guide health care’s transformation into a system based on value. One question: How well will this new generation of data-driven MDs deal with patients?

The surge of new MS treatments have been for the relapsing-remitting form of the disease. There’s hope for sufferers of a different form of MS. By homing in on CD20-positive B cells, ocrelizumab is able to knock them out and other aberrant B cells circulating in the bloodstream.

A flood of tests have insurers ramping up prior authorization and utilization review. Information overload is a problem. As doctors struggle to keep up, health plans need to get ahead of the development of the technology in order to successfully manage genetic testing appropriately.

Having the data is one thing. Knowing how to use it is another. Applying its computational power to the data, a company called RowdMap puts providers into high-, medium-, and low-value buckets compared with peers in their markets, using specific benchmarks to show why outliers differ from the norm.
Competition among manufacturers, industry consolidation, and capitalization on me-too drugs are cranking up generic and branded drug prices. This increase has compelled PBMs, health plan sponsors, and retail pharmacies to find novel ways to turn a profit, often at the expense of the consumer.
The development of recombinant DNA and other technologies has added a new dimension to care. These medications have revolutionized the treatment of rheumatoid arthritis and many of the other 80 or so autoimmune diseases. But they can be budget busters and have a tricky side effect profile.

Shelley Slade
Vogel, Slade & Goldstein

Hub programs have emerged as a profitable new line of business in the sales and distribution side of the pharmaceutical industry that has got more than its fair share of wheeling and dealing. But they spell trouble if they spark collusion, threaten patients, or waste federal dollars.

More companies are self-insuring—and it’s not just large employers that are striking out on their own. The percentage of employers who fully self-insure increased by 44% in 1999 to 63% in 2015. Self-insurance may give employers more control over benefit packages, and stop-loss protects them against uncapped liability.